Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Signs on Two Blue Cross Blue Shield Plans

NEW YORK (GenomeWeb News) – Response Genetics announced today contracts with Blue Cross and Blue Shield of Minnesota and Blue Cross and Blue Shield of Nebraska.

The Los Angeles-based molecular diagnostic company is now in-network with eight Blue Cross Blue Shield plans. Today's announcement follows agreements inked between Response Genetics and four payors last month.

The company offers genomic testing focused on lung, colon, and gastric cancer, as well as melanoma. The tests are used by physicians to help guide them in choosing therapeutic treatments for their patients.

Last week, Response Genetics launched a public offering of about 4.5 million shares of its common stock anticipated to raise $4.8 million in net proceeds.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.